Pulmonary Arterial Hypertension — Selexipag (ACT-293987) in Pulmonary Arterial Hypertension
Citation(s)
A Multicenter, Double-blind, Placebo-controlled Phase 3 Study Assessing the Safety and Efficacy of Selexipag on Morbidity and Mortality in Patients With Pulmonary Arterial Hypertension